Time filter

Source Type

Yamaguchi A.,Vitacain Pharmaceutical Co. | Ogino Y.,Vitacain Pharmaceutical Co. | Iwakoshi C.,Vitacain Pharmaceutical Co. | Karasawa K.,Vitacain Pharmaceutical Co. | Ohki M.,Industrial Research Ltd.
Japanese Journal of Cancer and Chemotherapy | Year: 2011

Special use-results surveillance was conducted to examine the safety and efficacy of trigger point (TP) therapy by Neovitacain® injection (NV) in the daily clinical treatment of myofascial pain in cancer patients. The case report forms of 175 patients were collected from 43 nationwide facilities and all of them were analyzed in terms of safety and efficacy. This treatment deeply impressed both patients and physicians; 75.4% and 78.3% respectively, over "the good." In addition, as the results of Wilcoxon's signed rank sum test for pain assessment (VAS, FS), both "Cumulative effect before and after treatment" and "Immediate effect before and after each administration" were confirmed to show a highly significant difference (p<0.0001). Side effects were observed in five of 175 cases (2.9%) but none of them were serious. Judging from the results of this study, TP therapy with NV was considered to be very useful for the treatment of myofascial pain in cancer patients.


Yamaguchi A.,Vitacain Pharmaceutical Co. | Ogino Y.,Vitacain Pharmaceutical Co. | Iwakoshi C.,Vitacain Pharmaceutical Co. | Karasawa K.,Vitacain Pharmaceutical Co. | Ohki M.,Industrial Research Ltd.
Japanese Journal of Cancer and Chemotherapy | Year: 2012

Our first report mentioned the analysis results of the safety and efficacy of trigger point (TP) therapy by Neovitacain® injection (NV) in the daily clinical treatment of myofascial pain in cancer patients. This time, we report additional considerations regarding the following points; Circled digit one Injection sites: they were concentrated on both sides of the spine, indicating that TPs could be easily formed on the points and near them to support the body's weight when patients were supine. Circled digit two Correlation between VAS and FS: VAS and FS were positively correlated in every measurement period. Circled digit three Patient satisfaction: many patients made several comments expressing feelings of satisfaction from this treatment. The comments were considered to reflect the patients' candid feelings. Therefore, all comments were classified according to the degree of patients' feeling of satisfaction. It may be possible to obtain much higher patient satisfaction by hearing out the voice of the patients. Judging from this study, TP therapy by NV for myofascial pain in cancer patients relieved the total pain of cancer patients. TP therapy has potential for obtaining high patient satisfaction.


Taguchi T.,Nagoya University | Yasui M.,Nagoya University | Kubo A.,Nagoya University | Kubo A.,Chubu University | And 4 more authors.
Pain | Year: 2013

Little is documented in the literature as to the function of muscle fascia in nociception and pain. The aim of this study was to examine the distribution of presumptive nociceptive nerve fibers, to characterize fascial thin-fiber sensory receptors, and to examine the spinal projection of nociceptive input from the rat crural fascia (CF). Nerve fibers labeled with specific antibodies to calcitonin gene-related peptide (CGRP) and peripherin were found to be densely distributed in the distal third of the CF. Thin-fiber receptors (Aδ- and C-fibers) responding to pinching stimuli to the CF with sharpened watchmaker's forceps, identified in vivo with the teased fiber technique from the common peroneal nerve, exist in the CF. Forty-three percent of the mechano-responsive fascial C-fibers were polymodal receptors (nociceptors) responding to mechanical, chemical (bradykinin), and heat stimuli, whereas almost all Aδ-fibers were responsive only to mechanical stimuli. Repetitive pinching stimulus to the CF induced c-Fos protein expression in the middle to medial part of superficial layers ie, laminae I-II of the spinal dorsal horn at segments L2 to L4, peaking at L3. These results clearly demonstrate the following: 1) peptidergic and non-peptidergic axons of unmyelinated C-fibers with nerve terminals are distributed in the CF; 2) peripheral afferents responding to noxious stimuli exist in the fascia, and 3) nociceptive information from the CF is mainly processed in the spinal dorsal horn at the segments L2 to L4. These results together indicate that the "muscle fascia," a tissue often overlooked in pain research, can be an important source of nociception under normal conditions. © 2013 International Association for the Study of Pain. Published by Elsevier B.V. All rights reserved.


PubMed | Vitacain Pharmaceutical Co., Chubu University, Nagoya University and Edith Cowan University
Type: Journal Article | Journal: European journal of pain (London, England) | Year: 2016

The current study investigated stretch variables and mechanical factors of lengthening contractions (LC) in the processes leading to muscular mechanical hyperalgesia in rats to understand mechanisms underpinning delayed onset muscle soreness (DOMS).Under isoflurane anaesthesia, ankle extensor muscles were loaded with repetitive LC with angular stretch velocities (50, 100, 200 and 400/s) at a fixed range of motion (ROM) of 90, and with ROMs (30, 60, 90 and 120) at a fixed velocity of 200/s.Mechanical hyperalgesia was observed in a velocity- and ROM-dependent manner. Under the fixed ROM, integrated torque generated during LC (iTqBoth velocity and ROM are pivotal variables determining the initiation of mechanical hyperalgesia. Neurotrophic factor-mediated peripheral mechanisms, but apparently not inflammatory changes caused by myofibre damage, are responsible for the mechanical hyperalgesia.Mechanical hyperalgesia appears after LC in a stretch velocity- and range of motion-dependent manner. The rate of torque increase and integrated torque are the crucial factors. Neurotrophic factor-mediated peripheral pain mechanisms without robust inflammatory changes caused by myofibre damage were required for this mechanical hyperalgesia.


PubMed | Vitacain Pharmaceutical Co.
Type: Journal Article | Journal: Gan to kagaku ryoho. Cancer & chemotherapy | Year: 2012

Our first report mentioned the analysis results of the safety and efficacy of trigger point (TP) therapy by Neovitacain injection (NV) in the daily clinical treatment of myofascial pain in cancer patients. This time, we report additional considerations regarding the following points; (1) Injection sites: they were concentrated on both sides of the spine, indicating that TPs could be easily formed on the points and near them to support the bodys weight when patients were supine. (2) Correlation between VAS and FS: VAS and FS were positively correlated in every measurement period. (3) Patient satisfaction: many patients made several comments expressing feelings of satisfaction from this treatment. The comments were considered to reflect the patients candid feelings. Therefore, all comments were classified according to the degree of patients feeling of satisfaction. It may be possible to obtain much higher patient satisfaction by hearing out the voice of the patients. Judging from this study, TP therapy by NV for myofascial pain in cancer patients relieved the total pain of cancer patients. TP therapy has potential for obtaining high patient satisfaction.


PubMed | Vitacain Pharmaceutical Co
Type: Journal Article | Journal: Gan to kagaku ryoho. Cancer & chemotherapy | Year: 2011

Special use-results surveillance was conducted to examine the safety and efficacy of trigger point (TP) therapy by Neovitacain injection (NV) in the daily clinical treatment of myofascial pain in cancer patients. The case report forms of 175 patients were collected from 43 nationwide facilities and all of them were analyzed in terms of safety and efficacy. This treatment deeply impressed both patients and physicians; 75.4% and 78.3% respectively, over the good. In addition, as the results of Wilcoxons signed rank sum test for pain assessment (VAS, FS), both Cumulative effect before and after treatment and Immediate effect before and after each administration were confirmed to show a highly significant difference (p<0. 0001). Side effects were observed in five of 175 cases (2. 9%) but none of them were serious. Judging from the results of this study, TP therapy with NV was considered to be very useful for the treatment of myofascial pain in cancer patients.

Loading Vitacain Pharmaceutical Co. collaborators
Loading Vitacain Pharmaceutical Co. collaborators